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Available online xxxxBackground: The use of pacemakers in the treatment of cardioinhibitory vasovagal syncope is controversial with a
mixed message from the limited evidence base. Single chamber leadless pacemakers have been shown to be an
effective alternative option to conventional pacemakers.
Objective: This study examines the use of leadless pacemakers in a cardioinhibitory vasovagal population in the
United Kingdom.
Methods:Observational data on 32 patients implantedwith theMicra Transcatheter Pacemaker System for vaso-
vagal syncope are presented. Data was collected on implant indications, implant procedure and follow up data
from 12 centres across the United Kingdom that had elected to use a Micra leadless pacemaker in this patient
population.
Results: 32 patients aged 37 ± 14 years (range 18 to 64 years) with 62% of the patients being female were re-
cruited to the study. Vasovagal syncope was diagnosed clinically and with the support of Holter monitoring,
tilt table testing and implantable loop recorders. The duration of symptoms was 8 ± 8 yrs. with an average fre-
quency of syncope being 4±6 times/year. TheMicra pacemakerwas successfully implanted in all patientswith a
major complication rate of 3.1%. Patients were followed up for 404±237 days (range 63–928 days). At followup
28 (87%) patients were free from symptoms.
Conclusions: This observational study suggests that the use of a single chamber leadless pacemaker in the treat-
ment of cardioinhibitory vasovagal syncope might be a reasonable clinical option.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Micra1. Background
The use of pacemakers in patients with cardioinhibitory vasovagal
syncope is controversial. Over the last decade it has fallen from a classUnit, Mailpoint 46, University
Road, Southampton SO16 6DY,
).
. This is an open access article under2A to 2B indication in international guidelines [1,2]. The reason for
this is that the evidence base in support of its efficacy is limited with
very few well-conducted studies in this area. Most fail to control the
studies by not having an appropriate placebo-controlled group. Many
patients with vasovagal syncope are young and so the consequences
of pacemaker therapy are more far reaching than in a conventional
older pacemaker population. It is well recognised that conventional
lead-based pacing is an effective therapy but not without complication,
both acute and long term.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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initial studies have suggested that this is a procedure that can be per-
formed safely and effectively and with favourable complication rates
[3]. TheMicra Transcatheter Pacing System (TPS) (Medtronic,Minneap-
olis, USA) is a catheter-delivered device that is placed via the femoral
veins using a deflectable catheter. This allows the deployment of a
fully functional rate responsive device (0.8 cc, 2 g) to enable pacing in
the right ventricle [4].
In this retrospective observational study, we present the short-term
United Kingdom experience of the use of a single chamber leadless
pacemaker in patients with cardioinhibitory vasovagal syncope.2. Methods
All 12 United Kingdom centres using the Micra Transcatheter Lead-
less Pacing System (Medtronic, Minneapolis, USA) were contacted by
the first author. A dedicated data collection tool was developed to cap-
ture theUKexperience of using theMicra TPS in patientswith vasovagal
cardioinhibitory syncope. Baseline characteristics and patient demo-
graphics at time of implantation, clinical indications and outcomes
were requested. Data are presented as means ± standard deviations
where appropriate.
The procedure of leadless pacing has been described previously [4].
Implanting centres were askedwhether they had used theMicra device
in patients with cardioinhibitory vasovagal syncope. If they responded
positively an anonymised questionnaire was sent to them requesting
data on the patient characteristics, the implant procedure and clinical
outcomes. This was a retrospective study that was not conducted as
part of a registry. Patient selection was made on clinical grounds
based on clinicians' views on whether the patient might be considered
suitable for a leadless pacemaker. All patients were given the option of
conventional or leadless pacemakers and selected the latter.Table 1
Clinical characteristics of patients implanted with Micra Leadless Pacemaker.
Patient
number
Age at
implant
Sex
(m/f)
Duration of symptoms
(years)
Frequency of syn
(per year)
1 50 m 5 6
2 24 m 10 3
3 23 f 1.5 12
4 18 f 1 4
5 58 f 3 2
6 37 m 2 6
7 25 m 16 2
8 21 m 7 1
9 35 f 5 2
10 57 f 8 3
11 46 m 38 26
12 40 f 2 3
13 31 f 6 1
14 22 f 8 0.5
15 29 m 20 1
16 34 f 3 4
17 55 f 2 2
18 27 m 5 1
19 27 f 20 6
20 18 f 4 1
21 37 f 7 0.5
22 31 f 5 0.25
23 20 f 12 2
24 35 m 8 2
25 64 m n/a 6
26 37 m n/a 0.5
27 44 f n/a 2
28 64 f n/a 2
29 37 f n/a 1
30 45 f n/a 20
31 63 m n/a 10
32 31 f 2 1
m – male, f – female, n/a – not available, ILR – implantable loop recorder.The diagnosis of cardioinhibitory vasovagal syncope was a clinical
diagnosis based upon history and use of Tilt Testing in some as sup-
ported in European Guidelines for the diagnosis of this condition [5].
The cardioinhibitory aspect was confirmed with monitoring and sinus
node disease was excluded by the observation of infrequent pauses
and associated symptoms.
Approval was received from the UK National Health Service (NHS)
Health Research Authority confirming that this study did not require
ethics submission and approval.
Consistent with published literature, major complications were de-
fined as a complication that lead to death, hospitalisation, prolonged
hospitalisation or loss of device function. Follow up was defined by
the local hospitals' routine follow up procedure for patients with vaso-
vagal syncope and patients with leadless pacemakers.
3. Results
3.1. Patient characteristics
32 patients were implanted with the Micra TPS between 2015 and
2018 for cardioinhibitory vasovagal syncope (Table 1). The mean age
of the population was 37 ± 14 years (range 18 to 64 years) with 62%
of the patients being female. The diagnosis of cardioinhibitory vasovagal
syncope was made on the basis of the clinical presentation and
supporting investigations. These included tilt table testing (32%), ambu-
latory Holter monitoring (16%) and implantable loop recorders (56%).
Some patients had more than one diagnostic supporting investigation.
The duration of symptoms was 8 ± 8 years with an average frequency
of syncopal events being 4 ± 6 events/year. The longest recorded RR′
intervals in the population was 13 ± 7 s. Data on 3/32 patients (9.4%)
was not available as they had been previously investigated at other hos-
pitals prior to conventional leaded pacemaker implantation and had
been referred for extraction of infected leaded pacemakers with re-cope Diagnostic modality
(tilt, Holter, ILR)
Longest RR′ interval
(secs)
Implant duration
(days)
Tilt 20 512
Tilt/ILR 21 186
Holter 24 312
ILR 9 171
Holter 8 131
ILR 8 373
ILR 7 424
Holter 6 842
ILR 11 928
ILR 12 119
Holter 4.9 484
ILR 4.2 616
ILR 8 484
ILR 19 932
ILR 10 787
Holter 5 131
ILR 15 309
ILR 11.2 337
ILR 29.8 361
Tilt 8 385
ILR 19 463
ILR 8 484
ILR 16 63
ILR 15 56
Tilt n/a 309
Tilt 27 227
Tilt 5 697
Tilt n/a 247
Tilt 6 278
Tilt n/a 449
Tilt 22 401
ILR 10 434
3P.R. Roberts et al. / IJC Heart & Vasculature 23 (2019) 100349implantation of Micra TPS. The number of patients recruited per center
was 2.7 ± 4.0 (mean ± S.D.).
3.2. Implant procedure
All patients were successfully implanted with the Micra TPS
(Table 2). One patient experienced a major complication (3.1%) with a
significantly elevated pacing threshold post procedure secondary to
microdisplacement. This was successfully retrieved and redeployed
one-week post implantation. Implant procedure time was defined as
the time from placement of the introducer sheath to removal of the
sheath. The mean duration of the procedure was 41 ± 16 min with
427 ± 237 s of fluoroscopy time. Two minor complications were re-
ported. One patient had ventricular ectopy noted after device deploy-
ment that settled and one patient had a minor groin haematoma that
was managed conservatively.
All patients were successfully deployed in ≦3 or less deployments
with themajority requiringonly 1 (62%). Themean acute pacing thresh-
old at implantation was 0.66± 0.62mV (pulse width 0.24ms), with an
R wave amplitude of 10.2 ± 4.7 V and impedance of 805 ± 234 Ohms.Table 2
Electrical characteristics and patient follow up (FU).
Patient
number
Implant
time
(mins)
Fluoroscopy
(sec)
Number of
deployments
R
wave
(mV)
1 25 460 2 15.4
2 70 300 2 7.4
3 60 243 1 4.4
4 46 475 1 6.1
5 n/a n/a 2 10.1
6 34 234 1 5.7
7 40 420 1 7
8 50 511 1 18.7
9 48 619 2 7.5
10 40 269 1 9.2
11 40 608 2 15.4
12 20 195 1 7.7
13 49 608 1 9.9
14 42 752 2 12.9
15 30 534 1 10.9
16 26 512 1 6.2
17 20 190 1 10.7
18 41 230 2 16.3
19 24 319 1 6.1
20 40 278 2 5.3
21 44 344 2 22.7
22 49 500 1 9.9
23 93 1467 1 9.5
24 40 218 1 8.9
25 n/a 470 3 4.3
26 n/a 108 1 7.7
27 n/a 282 1 20
28 n/a 282 2 13.6
29 n/a n/a 1 4.8
30 n/a 948 3 7.8
31 n/a 384 1 13.4
32 35 39 1 9.8A variety of different programming modes were used to treat this
patient population with 17 (53%) having just a VVI back up rate 35–
60 bpm. The remainder was programmed using hysteresis with lower
rates varying from 30 to 50 bpm and upper rates between 50 and
80 bpm (Table 2).3.3. Follow up
Patients were followed up according to National Guidelines with a
first follow up 4 to 6 weeks post implantation and then annually. Pa-
tients have been followed up for 404 ± 237 days (range 63–
928 days). Two patients were investigated for chest pain that was not
attributed to the Micra TPS device or implantation procedure following
appropriate investigations. At follow up 28/32 (87%) patients were free
from symptoms, 2 patients (6.3%) had not had formal follow up and 2
further patients (6.3%) had ongoing symptoms. One of these had expe-
rienced less event frequency and severity and one had persistent pre
syncopal events but no recurrence of syncope that had occurred prior
to pacemaker implantation.Threshold
(V at 0.24 ms)
Impedance
(Ω)
Pacing
mode
Symptoms
at follow
up
0.38 680 Hyst
40/70
No
3.5 800 VVI 50 No
0.5 680 VVI 40 No
0.38 820 Hyst
40/50
No
0.5 760 VVI 50 No FU
0.25 670 Back up No
0.63 620 Hyst
30/60
No
0.5 1500 VVI 40 No
0.5 550 VVI 60 No
0.25 810 Hyst
40/70
No FU
0.38 750 VVI 40 Yes
0.63 1430 Hyst
40/70
No
0.38 780 Hyst
40/80
No
0.63 620 Hyst
50/70
No
0.88 730 Hyst
30/80
No
0.5 670 Hyst
40/80
No
0.25 1150 Hyst
40/70
No
1.88 750 VVI 35 No
0.88 890 Hyst
40/70
No
0.375 790 Hyst
40/70
No
0.5 710 VVI 40 No
0.375 780 Hyst
40/80
Yes
0.5 520 Hyst
40/80
No
1.63 610 Hyst
40/80
No
0.5 1100 VVI 40 No
0.38 700 VVI 40 No
0.63 760 VVI 40 No
0.38 1270 VVI 40 No
0.5 660 VVI 40 No
0.75 750 VVI 40 No
0.5 710 VVI 40 No
9.8 740 VVI 40 No
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This observational, retrospective cohort study of the use of theMicra
TPS has indicated that in a population with cardioinhibitory vasovagal
syncope there is a high incidence of complete symptom resolution
(87%) following pacemaker implantation. The incidence of major com-
plications is very low and consistent with currently published data on
the use of the Micra TPS [3,4].
Conventionally, patients requiring pacing who are not in persistent
or permanent atrial fibrillation are considered for a dual chamber de-
vice. This concept applies to a population being considered for vasovagal
syncope so as to maintain as normal physiology as possible when there
may be both a cardioinhibitory and vasodepressor component to
symptoms. However, there are potential advantages to the use of
Micra TPS in this specific patient population, particularly related to
the avoidance of long-term complications of transvenous leads in a
young patient population. Based on the results of this study UK
device implanting physicians are using Micra TPS in patients with
cardioinhibitory vasovagal syncope. We did not explore the motivation
of physicians, but it may be that they consider that the theoretical ben-
efits of leadless pacemaker implantation may outweigh the benefits of
maintained atrioventricular synchronywith conventional dual chamber
leaded pacemakers.
Pacemaker implantation in patientswith vasovagal syncope remains
controversial. This condition is considered to have a favourable progno-
sis without the use of pacemaker implantation. The use of pacemaker
therapy in a younger population is not without risk. Risks includes
issues related to compromised venous access, cardiac implantable elec-
tronic device (CIED) infection and extraction and the ongoing require-
ment for long term follow up and device revisions. Many patients
requiring pacemakers at a young age will require multiple subsequent
interventions. This may include the placement of additional leads due
to lead failure, lead extraction and the inherent risk of device-based in-
fection with each subsequent surgical intervention. The evidence base
for pacemaker implantation in this population is weak and dominated
by small studies lacking control groups or cross over design and with
significant risk bias.
The Vasovagal Pacemaker Study (VPS Study) was one of the first
randomised studies of the use of dual chamber pacemaker implantation
in vasovagal syncope [6]. This study of only 27 patients randomised pa-
tients with cardioinhibitory VVS to dual chamber pacing versus stan-
dard therapy. The study was stopped early by the Data Monitoring
Committee as there was a significant difference between the rate of re-
current syncope (22% versus 70% in the standard care group). This study
was not blinded and as itwas stopped early long term followup data are
not available.
Three subsequent studies examined the use of dual chamber pace-
maker implantation compared to placebo using OVO pacing mode for
the placebo-controlled arm. The second vasovagal pacemaker study
(VPS II) showed a 42% recurrence rate of syncopal episodes in the pla-
cebo group compared to 33% in the active treatment group (p = 0.14)
[7]. The Vasovagal Syncope and Pacing Trial (SYNPACE) examined 29
patients with VVS and showed recurrent syncope in 38% of the placebo
group and 50% of the treatment group (p – ns) [8]. ISSUE 3 used im-
plantable loop recorders to identify patients with cardioinhibitory or
mixed vasovagal syncope. 77 patients underwent dual chamber pace-
maker implantation and were randomised to DDD or ODO pacing
modes. Syncope recurred in 57% of the placebo group and 25% of
those paced (p= 0.039) [9]. The data supporting pacing in this popula-
tion are, therefore, mixed but arguably in small studies. As a conse-
quence, the indication for pacing in VVS has gone from a 2A to 2B
indication in the guidelines [1,2]. It is important to note that there are
significant differences in the ages of the populations in these studies
compared to our study. In ISSUE 3 patients under the age of 40 years
were excluded and the mean age of the overall study population was
65 years compared to 37 years in our study [9].In our study population the degree of bradycardia was at the more
extreme end of the spectrum with a mean RR’ interval of 13 s (range
4.2–29.8 s). It might be argued that in a population with such profound
symptomatic pauses associated with VVS that VVI pacing is likely to be
better than asystole in haemodynamic terms. The relative high therapy
success rate in this study is unlikely to represent superiority of single
chamber leadless pacing but more likely to reflect the highly selective
nature of the patients in this study with profound pauses associated
with VVS. Furthermore, as events are short lived the frequency of events
(0.25 to 26/year) is unlikely to have an impact on the perceived benefit
of single chamber leadless pacing compared to dual chamber pacing. In
some patients the symptom burden of vasovagal syncope may resolve
with time. The Micra TPS has the unique ability to be programmed off.
It could be a reasonable strategy to program the device off towards
the end of the device's life to evaluate whether further pacing therapy
is justified. Early studies of theMicra device have indicated that battery
longevitymay be ashigh as 14.9 years [10]. Based upon themeanpacing
threshold of 0.66 mV seen in this study and a low pacing requirement
projected longevity is 14.6 years. Patients with vasovagal syncope are
likely to have low pacing percentages due to the infrequent nature of
the condition. If patients have ongoing symptoms with a pacing indica-
tion, then management options may include implantation of a second
Micra TPS device (with or without extraction of the old device) or a
switch to conventional leaded pacemaker implantation having con-
served the vasculature for a number of years with the use of an initial
leadless pacing strategy. There are limited data on extraction of leadless
pacemakers. Although the long-term sequelae of retained expired lead-
less pacemakers in humans are unknown, it is likely that avoidance of
retained transvenous pacing leads or extraction of transvenous pacing
leads in young patients without an ongoing indication for pacing will
be beneficial. Even if future device re-implantation is indicated, it is dif-
ficult to predict the nature of CIED that will be viable therapeutic op-
tions in 10 years' time.
4.1. Study limitations
This is a multi-centre, observational study and can only describe a
practice in a highly selected population within a single country. Wider
generalisability is challenging but the observations of this study justify
a well conducted prospective randomised study of the of leadless pace-
maker implantation in patients with cardioinhibitory vasovagal syn-
cope. The follow up of patients in this study is relatively short at 404
± 237 days (range 63–928 days). However, Table 1 demonstrates that
the selected population had a high rate of syncopal episodes that
would justify clinical interpretation during the follow up period.
5. Conclusions
This observational study suggests that the single chamber leadless
pacemaker implantation may be a reasonable clinical option in a highly
selected group of patients with profound bradycardia associated with
cardioinhibitory vasovagal syncope. This study has shown that the
Micra TPS can be implanted effectively and safely with a high level of
symptom improvement at early follow up.
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